Two Sigma Securities’s Akari Therapeutics AKTX Stock Holding History

Two Sigma Securities’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-494	Closed	-$20K	–	1441
2025 Q3	$20K	Buy	+494	New	+$19.2K	﹤0.01%	1142
2023 Q3	–	Sell	-22	Closed	-$2.99K	–	2887
2023 Q2	$2.99K	Buy	+22	New	+$3.18K	﹤0.01%	2689
2023 Q1	–	Sell	-17	Closed	-$6.31K	–	2600
2022 Q4	$6.31K	Buy	+17	New	+$7.03K	﹤0.01%	2431
2022 Q3	–	Sell	-41	Closed	-$33K	–	2555
2022 Q2	$33K	Buy	+41	New	+$36.4K	﹤0.01%	1888
2020 Q1	–	Sell	-16	Closed	-$22K	–	1311
2019 Q4	$22K	Buy	+16	New	+$23.6K	﹤0.01%	2259
2019 Q2	–	Sell	-26	Closed	-$74K	–	2048
2019 Q1	$74K	Buy	+26	New	+$49.6K	﹤0.01%	1590

Other funds holding AKTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $240M AUM

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Securities's AKTX Position: Q4 2025 in Review

Two Sigma Securities sold out of Akari Therapeutics (AKTX) in Q4 2025, closing a stake of 494 shares — an estimated $20K sold.

Two Sigma Securities first reported a position in AKTX in Q1 2019 and held it in 6 quarters. The position peaked at $74K in Q1 2019. 19 funds tracked by Wall St. Rank hold AKTX as of Q4 2025.

Two Sigma Securities reported no remaining Akari Therapeutics position as of Q4 2025 after selling out during the quarter.
Two Sigma Securities sold 494 Akari Therapeutics shares in Q4 2025, an estimated $20K.
Two Sigma Securities first reported a position in Akari Therapeutics in Q1 2019 and held it in 6 quarters.
Two Sigma Securities's Akari Therapeutics position peaked at $74K in Q1 2019.
19 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.